article · Archiv der Pharmazie
The development of triazole-sulfonamide hybrids is an emerging frontier in medicinal chemistry, combining the clinically validated sulfonamide core with a triazole linker. This structural synergy has yielded potent and selective carbonic anhydrase inhibitors (CAIs) targeting various human and mycobacterial isoforms. Besides CA inhibition, these hybrids also exhibit multi-target binding. They can also interact with vascular endothelial growth factor receptor-2 (VEGFR-2), telomerase, and other oncological and microbial targets, highlighting their broader therapeutic potential against cancer, tuberculosis, and neuropathic diseases. This review provides an overview of synthetic methods, structure-activity relationships (SAR), and isoform selectivity of triazole-sulfonamide conjugates reported from 2020 to 2025. Unlike other reviews focused on CA inhibitory properties, we highlight the multi-inhibitor pharmacological profile of these hybrids and demonstrate their applications in multi-target drug design.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1002/ardp.70269
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
